DE3588177D1 - Verfahren zur Feststellung der Anwesenheit eines selbstimmunen Antikörpers - Google Patents

Verfahren zur Feststellung der Anwesenheit eines selbstimmunen Antikörpers

Info

Publication number
DE3588177D1
DE3588177D1 DE3588177T DE3588177T DE3588177D1 DE 3588177 D1 DE3588177 D1 DE 3588177D1 DE 3588177 T DE3588177 T DE 3588177T DE 3588177 T DE3588177 T DE 3588177T DE 3588177 D1 DE3588177 D1 DE 3588177D1
Authority
DE
Germany
Prior art keywords
self
procedure
determining
immune antibody
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3588177T
Other languages
English (en)
Other versions
DE3588177T2 (de
Inventor
Jack D Keene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of DE3588177D1 publication Critical patent/DE3588177D1/de
Application granted granted Critical
Publication of DE3588177T2 publication Critical patent/DE3588177T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
DE3588177T 1984-12-31 1985-12-18 Verfahren zur Feststellung der Anwesenheit eines selbstimmunen Antikörpers Expired - Lifetime DE3588177T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/687,908 US4751181A (en) 1984-12-31 1984-12-31 Methods and compositions useful in the diagnosis and treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
DE3588177D1 true DE3588177D1 (de) 1998-04-09
DE3588177T2 DE3588177T2 (de) 1998-10-29

Family

ID=24762355

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3588177T Expired - Lifetime DE3588177T2 (de) 1984-12-31 1985-12-18 Verfahren zur Feststellung der Anwesenheit eines selbstimmunen Antikörpers
DE3588082T Expired - Lifetime DE3588082T2 (de) 1984-12-31 1985-12-18 Verfahren und zusammensetzungen zur verwendung in der diagnose und behandlung autoimmuner krankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3588082T Expired - Lifetime DE3588082T2 (de) 1984-12-31 1985-12-18 Verfahren und zusammensetzungen zur verwendung in der diagnose und behandlung autoimmuner krankheiten

Country Status (5)

Country Link
US (3) US4751181A (de)
EP (2) EP0690307B1 (de)
JP (2) JP2680811B2 (de)
DE (2) DE3588177T2 (de)
WO (1) WO1986004093A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
CA1327162C (en) * 1987-04-09 1994-02-22 Board Of Trustees Of The Leland Stanford Junior University (The) Method for prophylactically treating an individual for an autoimmune disease
CA1313818C (en) * 1987-06-03 1993-02-23 Ross Leon Coppel Nuclear antigen la
US5196307A (en) * 1988-03-29 1993-03-23 The Johns Hopkins University Cloned human centromere autoantigen
US5645998A (en) 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US6811989B1 (en) * 1989-02-17 2004-11-02 Bayer Corporation Pancreatic islet cell antigens obtained by molecular cloning
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5162515A (en) * 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5391785A (en) * 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
IE922292A1 (en) * 1991-07-15 1993-01-27 Jolla Pharma Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
WO1993020803A1 (en) * 1992-04-22 1993-10-28 Molecular Rx, Inc. Method and composition for the treatment of disorders involving immunological dysfunction
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5518881A (en) * 1993-11-02 1996-05-21 Flinders Medical Centre Transfected cell lines expressing autoantigens and their use in immunoassays for the detection of autoimmune disease
US5492807A (en) * 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
CA2138932A1 (en) * 1993-12-28 1995-06-29 Masako Wagatsuma Mutant proteins of human dna topoisomerase i
DE69529219T2 (de) * 1994-07-01 2003-11-06 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Helicobacter proteine und impstoffe
US5573911A (en) * 1994-10-03 1996-11-12 Lifecodes Corp. Methods and materials for detecting autoimmune antibodies
US6159748A (en) * 1995-03-13 2000-12-12 Affinitech, Ltd Evaluation of autoimmune diseases using a multiple parameter latex bead suspension and flow cytometry
US5691204A (en) * 1995-04-21 1997-11-25 Abbott Laboratories Compositions and methods for the rapid analysis of reticulocytes
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
WO1997025429A1 (en) * 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US8815517B2 (en) * 1999-12-28 2014-08-26 Ribonomics, Inc. Methods for identifying functionally related genes and drug targets
EP1254370A1 (de) * 1999-12-28 2002-11-06 Ribonomics, Inc. Verfahren zum isolierung und charakterisierung von mrna-protein komplexen
JP4834810B2 (ja) * 2000-05-26 2011-12-14 株式会社医学生物学研究所 抗ｅｎａ抗体の測定方法及び測定キット
EP1292337A2 (de) 2000-06-08 2003-03-19 La Jolla Pharmaceutical Polyethylenoxid mit hohem molekulargewicht enthaltende multivalenz-plattformmoleküle
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
ATE542545T1 (de) * 2001-05-24 2012-02-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
CA2458854A1 (en) * 2001-08-31 2003-03-06 Chiron Srl Helicobacter pylori vaccination
JP4108601B2 (ja) * 2001-09-06 2008-06-25 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィク 修飾ペプチドおよび自己免疫疾患を治療するためのその使用
US20040241775A1 (en) * 2002-11-14 2004-12-02 The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods and kits for determining risk of pre-term delivery
JP2006524056A (ja) * 2003-04-07 2006-10-26 リボノミックス， インコーポレイテッド グルコース代謝および脂質代謝に関与する治療標的を同定するための方法
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EA016083B1 (ru) * 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
CN101489573B (zh) * 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
HUP0800448A2 (en) * 2008-07-21 2011-02-28 Pecsi Tudomanyegyetem Diagnosis of systemic diseases
WO2010024089A1 (ja) * 2008-09-01 2010-03-04 学校法人慶應義塾 皮膚筋炎の診断方法および診断キット
US20110177525A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
US20110295175A1 (en) * 2010-03-16 2011-12-01 Marv Enterprises Llc Sequential Extracoporeal Treatment of Bodily Fluids
DE102010039018B4 (de) 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La Antikörper und ihre Anwendung zum Immunotargeting
WO2012068107A2 (en) * 2010-11-17 2012-05-24 University Of Florida Research Foundation, Inc. Autoantibody to rna-protein complex detected by quantitative pcr
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
CN109422814B (zh) * 2017-08-29 2024-02-06 博生吉医药科技(苏州)有限公司 一种抗La/SSB嵌合体抗原修饰的NK细胞、其制备方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4375414A (en) * 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3897212A (en) * 1973-01-30 1975-07-29 Albert Einstein Medical Center Test for systemic lupus erythematosus
FR2366023A1 (fr) * 1976-07-30 1978-04-28 Inst Nat Sante Rech Med Procede et appareil de reglage des conditions d'hemodialyse
JPS5348498A (en) * 1976-10-14 1978-05-01 Seiko Epson Corp Display device
CS200909B1 (en) * 1977-12-23 1980-10-31 Petr Slovak Haemodlialysation device
JPS54148548A (en) * 1978-05-02 1979-11-20 Seiko Epson Corp Liquid crystal display panel
DE2853453A1 (de) * 1978-12-11 1980-06-19 Behringwerke Ag Mittel zur therapie von immunkomplexerkrankungen
US4254097A (en) * 1979-11-05 1981-03-03 American Hospital Supply Corporation Method of detecting antibodies to human thyroglobulin
JPS57118220A (en) * 1981-01-13 1982-07-23 Toyobo Co Ltd Polarizing plate having transparent conductive layer
US4381004A (en) * 1981-01-15 1983-04-26 Biomedics, Inc. Extracorporeal system for treatment of infectious and parasitic diseases
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
AU568067B2 (en) * 1981-10-23 1987-12-17 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
JPS5887538A (ja) * 1981-11-20 1983-05-25 Hitachi Ltd 液晶表示素子
EP0096520A3 (de) * 1982-06-03 1984-12-27 Agroproduits S.A. Antigennachweis:Rheumatoide Arthritis
EP0140308B2 (de) * 1983-10-20 2001-10-17 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS
EP0155676A3 (de) * 1984-03-19 1988-02-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Gewinnung der globulären Domäne von Basalmembrankollagen und immunologische Bestimmung von Basalmembranmaterial und Autoantikörpern
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US6617496B1 (en) * 1985-10-16 2003-09-09 Monsanto Company Effecting virus resistance in plants through the use of negative strand RNAs
WO1987003451A1 (en) * 1985-12-05 1987-06-18 Fred Hutchinson Cancer Research Center Anti-sense rna for treatment of retroviral disease states
US4865970A (en) * 1986-02-28 1989-09-12 Hoffmann-La Roche Inc. Method of detecting ribosomal protein antibodies in systemic lupus erythematosus

Also Published As

Publication number Publication date
EP0690307B1 (de) 1998-03-04
EP0690307A1 (de) 1996-01-03
EP0205579A4 (de) 1988-04-13
WO1986004093A1 (en) 1986-07-17
US4751181A (en) 1988-06-14
US5721110A (en) 1998-02-24
EP0205579A1 (de) 1986-12-30
JPH09166596A (ja) 1997-06-24
JP2736322B2 (ja) 1998-04-02
JPS62501314A (ja) 1987-05-21
US5541291A (en) 1996-07-30
DE3588082D1 (de) 1996-03-28
EP0205579B1 (de) 1996-02-14
DE3588177T2 (de) 1998-10-29
DE3588082T2 (de) 1996-10-02
JP2680811B2 (ja) 1997-11-19

Similar Documents

Publication Publication Date Title
DE3588177D1 (de) Verfahren zur Feststellung der Anwesenheit eines selbstimmunen Antikörpers
ATA356685A (de) Verfahren zur quantitativen messung von kohlenwasserstoffen
DE69008211D1 (de) Verfahren zur Bestimmung der Länge eines Risses.
PT74887A (de) Verfahren zur verbesserung der fullfahigkeit von tabaken
ATA38182A (de) Verfahren zur beurteilung von holzoberflaechen
DE3751940D1 (de) Verfahren zur Messung des Zustandes von Fluiden
DE3764763D1 (de) Verfahren zur toleranzkompensation eines positionsgebersignals.
DK617584D0 (da) Analysemetoder for ligander
DE3682045D1 (de) Verfahren zur messung der zeitverzoegerung eines kabels.
DE69029530D1 (de) Verfahren zur Bestimmung der Lebensdauer einer Verbindung
AT384544B (de) Verfahren zur bestimmung der beweglichkeit von koerperteilen
AT387162B (de) Einrichtung zur entzunderung der oberflaeche eines streifens
DE3679597D1 (de) Verfahren zur vermeidung der korrosion metallischer werkstoffe.
AT387786B (de) Verfahren zur vergasung von kohlenstoffhaeltigen materialien
AT374928B (de) Verfahren zur bestimmung des antikoerperspiegels eines serums
DE69120513D1 (de) Verfahren zur schnellen Messung von Spurbestandteilen
AT369033B (de) Verfahren zur bestimmung der c1-esterase-inhibitor-aktivitaet von c1-esterase-inhibitor-haeltigen proben
ATA355681A (de) Messsystem zur messung der laengs- und querausdehnung eines werkstuecks
DE69424004D1 (de) Trommelführungsmessverfahren zur genauen Ermittlung der Trommelführungsmessverfahren
DD139300A1 (de) Verfahren zur bestimmung der restlebensdauer eines zeitstandbeanspruchten bauteiles
ATA220379A (de) Verfahren zur verhingerung der kondensation von klebstoffmischungen
ATA239981A (de) Pruefkoerper zur ermittlung von bruchmechanischen kennwerten
ATA274189A (de) Verfahren zur entkieselung der ablauge
DD135935A1 (de) Verfahren zur erfassung der stuetzkraefte von tagebaugeraeteoberbauen
DD207472A3 (de) Verfahren zur ermittlung der strukturfestigkeit des bodens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition